ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
ConditionCommunity Acquired Pneumonia (CAP)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSocieta Italiana di Pneumologia
About this trial
This multicentric, prospective study aims at:
evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
AIDS,
Aplastic anemia;
Asplenia;
Hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma);
Disqualifiers
None
Trial population
Immunosuppressed patients with Community-Acquired Pneumonia will be enrolled during hospitalization in Italian Pneumology, Infectious Diseases and Emergency Departments selected on their specific experteeze and know-how. Upon discharge, patients will be followed up at 30 days, 3 months, 6 months and 12 months after discharge.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
In-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Recording in-hospital mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Time frame
During hospitalization corresponding to study enrollment (1 day to 2 weeks of hospitalization on average)Secondary outcomes
1
Time to clinical stability
Time to clinical stability calculated as the number of days from the date of admission to the date that the patient meets clinical stability criteria, up to 8 days. Clinical stability is defined as follows: improved clinical signs (improved cough and shortness of breath), lack of fever for at least 8 hours, improving leukocytosis (decreased at least 10% from the previous day), and tolerating oral intake.
Time frame
DAY 1 to 82
Mortality for all causes in immunocompromised patients with CAP
Mortality for all causes in immunocompromised patients with CAP enrolled in the study.
Time frame
30 days, 3 months, 6 months and 12 months after hospital discharge.3
New hospitalizations in immunocompromised patients with CAP.
Recording new hospitalizations in immunocompromised patients with CAP enrolled in the study.
Time frame
30 days, 3 months, 6 months and 12 months after hospital discharge.4
Prevalence of cardiovascular events in immunocompromised patients with CAP.
Prevalence of cardiovascular events in immunocompromised patients with CAP enrolled in the study.
Time frame
30 days, 3 months, 6 months and 12 months after hospital discharge.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov